I refer the reader to the recently released Pfizer document entitled “2.4 NONCLINICAL OVERVIEW”.
Let’s get the definitions out of the way.
Carcinogenicity is descriptive of the ability to induce cancer and remember, a carcinogen does not necessarily have to be a toxin!
Let’s even do cancer. Cancer is any dis-ease in which normal cells are damaged and the balance of growth versus death/removal is skewed toward growth. It is, in my opinion a metabolic disorder, but that’s definitely for another Substack.
It is important to know that genetic mutations can result from DNA copying mistakes that occur during cell division, from exposure to ionizing radiation (like from medical X-rays - physical mutagen), exposure to chemicals (chemical mutagens) or even by infection by viruses like Human Papillomavirus (HPV)2 (biological mutagen). So they say. I am not entirely-convinced anymore.
We’ve already seen studies published that have shown disruption in double-stranded DNA repair via specific enzymes and indications of reverse transcription of modified spike RNA to DNA in in vivo systems and reverse transcription and integration of SARS-nCoV-2 RNA into human DNA.3 4 5
Mechanistically, we found that the spike protein localizes in the nucleus and inhibits DNA damage repair by impeding key DNA repair protein BRCA1 and 53BP1 recruitment to the damage site.
This is bad news for DNA repair. No DNA repair. No normal functionality of physiological processes. Dis-eases abound and don’t get me started on aging. Kind of like throwing a spike-shaped wrench made out of sand into a finely-tuned engine.
But I am not writing this Substack to talk too much about the implications or effects. That’s what the papers are for. I am writing this today to document the fact that there were NO genotoxicity or carcinogencinity studies done in the context of the COVID-19 modified RNA LNP-based products during pre-market testing. Why, you ask?
Because the genetic material and the fats were not expected to have genotoxic, carcinogenic or tumorigenic potential.